Hantz Financial Services Inc. Has $4.50 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY

Hantz Financial Services Inc. reduced its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 13.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 11,323 shares of the biopharmaceutical company’s stock after selling 1,823 shares during the period. Hantz Financial Services Inc.’s holdings in Alnylam Pharmaceuticals were worth $4,503,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Mediolanum International Funds Ltd acquired a new position in shares of Alnylam Pharmaceuticals in the third quarter valued at $11,389,000. iA Global Asset Management Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 979.5% in the fourth quarter. iA Global Asset Management Inc. now owns 17,780 shares of the biopharmaceutical company’s stock valued at $7,070,000 after purchasing an additional 16,133 shares during the last quarter. Perpetual Ltd acquired a new position in shares of Alnylam Pharmaceuticals in the fourth quarter valued at $2,004,000. Vanguard Group Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 2.0% in the third quarter. Vanguard Group Inc. now owns 13,565,452 shares of the biopharmaceutical company’s stock valued at $6,185,846,000 after purchasing an additional 268,313 shares during the last quarter. Finally, Envestnet Asset Management Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 24.2% in the third quarter. Envestnet Asset Management Inc. now owns 118,964 shares of the biopharmaceutical company’s stock valued at $54,248,000 after purchasing an additional 23,168 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have commented on ALNY shares. Jefferies Financial Group reiterated a “hold” rating and issued a $330.00 price objective (down from $522.00) on shares of Alnylam Pharmaceuticals in a report on Monday, March 16th. Chardan Capital restated a “buy” rating and issued a $425.00 price target on shares of Alnylam Pharmaceuticals in a research note on Wednesday, March 25th. Weiss Ratings upgraded shares of Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Wall Street Zen upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Finally, HC Wainwright restated a “buy” rating and issued a $510.00 price target on shares of Alnylam Pharmaceuticals in a research note on Tuesday, May 5th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $463.13.

Alnylam Pharmaceuticals Stock Performance

ALNY stock opened at $297.45 on Tuesday. The company has a debt-to-equity ratio of 0.94, a quick ratio of 3.06 and a current ratio of 3.13. The company’s 50-day simple moving average is $310.76 and its 200 day simple moving average is $358.07. Alnylam Pharmaceuticals, Inc. has a 52 week low of $284.19 and a 52 week high of $495.55. The company has a market capitalization of $39.71 billion, a PE ratio of 81.27 and a beta of 0.31.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 EPS for the quarter, beating the consensus estimate of $0.87 by $1.12. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The business had revenue of $1.17 billion for the quarter, compared to the consensus estimate of $1.12 billion. During the same period in the prior year, the company posted ($0.44) earnings per share. Alnylam Pharmaceuticals’s revenue was up 96.4% compared to the same quarter last year. As a group, sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 7.36 earnings per share for the current year.

Insider Activity

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 6,799 shares of the stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $327.65, for a total transaction of $2,227,692.35. Following the sale, the chief executive officer directly owned 98,628 shares in the company, valued at $32,315,464.20. This represents a 6.45% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Pushkal Garg sold 1,775 shares of the stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $319.74, for a total transaction of $567,538.50. Following the sale, the executive vice president owned 23,406 shares in the company, valued at $7,483,834.44. The trade was a 7.05% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 21,255 shares of company stock valued at $6,930,337. Company insiders own 0.86% of the company’s stock.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.